Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05580445

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

A Phase Ib/II, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antineoplastic Activity of CT-707 in Combination With Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

Sponsor: Shouyao Holdings (Beijing) Co. LTD

Conditions Advanced Pancreatic Cancer

Interventions CT-707 Gemcitabine Toripalimab

Updated 5 times since 2022 Last updated: Nov 20, 2023 Started: Aug 11, 2022 Primary completion: Aug 11, 2024 Completion: Aug 11, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Advanced Pancreatic Cancer, this trial is ongoing. The trial is conducted by Shouyao Holdings (Beijing) Co. LTD and has accumulated 5 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Nov 2022 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shouyao Holdings (Beijing) Co. LTD

Data source: Shouyao Holdings (Beijing) Co. LTD

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China